ArticleGland surgery2012
Expressions of D2-40, CK19, galectin-3, VEGF and EGFR in papillary thyroid carcinoma.
Article in Gland surgery, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.
- Galectin-3 Performance in Histologic a Cytologic Assessment of Thyroid Nodules: A Systematic Review and Meta-Analysis.International journal of molecular sciences · 2017Pooled it
- Article
- Serum galectin-3 as a biomarker for screening, early diagnosis, prognosis and therapeutic effect evaluation of pancreatic cancer.Journal of cellular and molecular medicine · 2020Article
- CircRNA circ_0067934 Overexpression Correlates with Poor Prognosis and Promotes Thyroid Carcinoma Progression.Medical science monitor : international medical journal of experimental and clinical research · 2019Article
- Expression of Vascular Endothelial Growth Factor and Its Receptors in Thyroid Nodular Hyperplasia and Papillary Thyroid Carcinoma: A Tertiary Health Care Centre Based StudyAsian Pacific journal of cancer prevention : APJCP · 2019Article
- Diagnostic significance of CK19, galectin-3, CD56, TPO and Ki67 expression and BRAF mutation in papillary thyroid carcinoma.Oncology letters · 2018Article
- Extracellular galectin-3 facilitates colon cancer cell migration and is related to the epidermal growth factor receptor.American journal of translational research · 2018Article
- Diagnostic accuracy of CK-19, Galectin-3 and HBME-1 on papillary thyroid carcinoma: a meta-analysis.International journal of clinical and experimental pathology · 2017Article
- Galectin-3 may serve as a potential marker for diagnosis and prognosis in papillary thyroid carcinoma: a meta-analysis.OncoTargets and therapy · 2016Article
- Gene expression profile analyze the molecular mechanism of CXCR7 regulating papillary thyroid carcinoma growth and metastasis.Journal of experimental & clinical cancer research : CR · 2015Article
- miR-219-5p modulates cell growth of papillary thyroid carcinoma by targeting estrogen receptor α.The Journal of clinical endocrinology and metabolism · 2015Article
- CK19 IS A USEFUL MARKER IN DISTINGUISHING FOLLICULAR VARIANT OF PAPILLARY THYROID CARCINOMA FROM BENIGN THYROID LESIONS WITH FOLLICULAR GROWTH PATTERN.Acta endocrinologica (Bucharest, Romania : 2005)Article
- The Prognostic Role of Lymphatic Vessel Density in Papillary Thyroid Carcinoma: A Systematic Review and Meta-analysis.Cancer diagnosis & prognosisReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the expressions of D2-40, CK19, galectin-3, VEGF, and EGFR in papillary thyroid carcinoma and their clinical significances.
methodsThe expressions of D2-40, CK19, galectin-3, VEGF, and EGFR in 38 cases of papillary thyroid carcinoma and 12 cases of thyroid papillary hyperplasia were detected by immunohistochemical staining.
resultsThe positive expression rates of D2-40, CK19, Galectin-3, VEGF and EGFR in patients with papillary thyroid carcinoma were all significantly higher than those in patients with thyroid papillary hyperplasia (all P<0.05). The expressions of D2-40, VEGF, and EGFR in papillary thyroid carcinoma with lymph node metastasis were significantly higher than those without lymph node metastasis (P<0.05). The expressions of GK19 and galectin-3 showed no significant differences between the papillary thyroid carcinomas with and without lymph node metastasis (P>0.05).
conclusionsThe detection of D2-40, CK19, galectin-3, VEGF, and EGFR is helpful for the diagnosis and differential diagnosis of papillary thyroid carcinoma and thyroid papillary hyperplasia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.